辛伐他汀辅助治疗蛛网膜下腔出血的有效性及安全性  

CLINICAL EFFECT AND SAFETY OF SIMVASTATIN IN ADJUVANT THERAPY FOR SUBARACHNOID HEMORRHAGE

作　　者：陈运江 韩志新 CHEN Yunjiang;HAN Zhixin(Department of Neurosurgery, Anyang People’s Hospital, Anyang 455000, China)

机构地区：[1]安阳市人民医院神经外科,河南安阳4550001 [2]安阳市人民医院烧伤整形科,河南安阳4550001

出　　处：《精准医学杂志》2021年第1期84-86,91,共4页Journal of Precision Medicine

基　　金：河南省医学科技攻关计划联合共建项目(LHGJ-20191274)。

摘　　要：目的探究辛伐他汀辅助治疗蛛网膜下腔出血(SAH)的有效性及安全性。方法选取我院2017年1月—2018年8月收治的SAH患者91例,随机分为对照组(47例)及试验组(44例),对照组给予常规治疗,试验组在常规治疗基础上加用辛伐他汀进行辅助治疗,比较两组患者治疗前后脑脊液和血清中炎症相关因子、内皮素(ET)、一氧化氮(NO)水平及神经功能、不良反应情况。结果最终两组各43例患者完成该研究,两组不良反应发生率比较差异无显著性(P>0.05)。治疗前两组患者脑脊液中白细胞介素6(IL-6)、基质金属蛋白酶2水平,血清中IL-6、肿瘤坏死因子α、IL-17、ET、NO、S100-β水平及NIHSS评分比较,差异均无显著性(P>0.05);治疗后两组中上述指标与治疗前比较,均显著降低(t=2.114~30.531,P<0.05);两组治疗前后上述指标的差值比较,差异有显著性(t=6.366~24.697,P<0.05)。两组不良反应发生率比较,差异无显著性(P>0.05)。结论辛伐他汀辅助治疗SAH能有效缓解患者炎症反应,改善患者血管及神经功能,且安全性较好。Objective To investigate the clinical effect and safety of simvastatin in the adjuvant therapy for subarachnoid hemorrhage(SAH).Methods A total of 91 patients with SAH who were admitted to our hospital from January 2017 to August 2018 were enrolled and randomly divided into control group with 47 patients and experimental group with 44 patients.The patients in the control group were given conventional treatment,and those in the experimental group were given simvastatin as adjuvant therapy in addition to the treatment in the control group.The two groups were compared in terms of the levels of inflammation-related factors,endothelin(ET),and nitric oxide(NO)in cerebrospinal fluid and serum,as well as neurological function and adverse reactions.Results A total of 43 patients in each group completed the study,and there was no significant difference in the incidence rate of adverse reactions between the two groups(P>0.05).Before treatment,there were no significant differences between the two groups in the levels of interleukin-6 and matrix metalloproteinase-2 in cerebrospinal fluid,the serum levels of interleukin-6,tumor necrosis factor-α,interleukin-17,ET,NO,and S100-β,and NIHSS score(P>0.05).After treatment,both groups had significant reductions in the above indicators(t=2.114-30.531,P<0.05),and there were significant differences in the changes in the above indications after treatment between the two groups(t=6.366-24.697,P<0.05).There was no significant difference in the incidence rate of adverse reactions between the two groups(P>0.05).Conclusion For patients with SAH,adjuvant therapy with simvastatin can effectively alleviate inflammatory response and improve vascular and neurological functions with good safety.

关 键 词：辛伐他汀 蛛网膜下腔出血 白细胞介素类 基质金属蛋白酶2 肿瘤坏死因子Α 内皮缩血管肽类 一氧化氮 治疗结果 

分 类 号：R743.35[医药卫生—神经病学与精神病学]